Selvita S.A.
ISIN: PLSLVCR00029 | Ticker: SLV | LEI: 25940057WQ9YP5MOQF28
Country: Poland
We are one of the largest preclinical contract research organizations in Europe, driven by a clear mission:
to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.
We have grown from a 20-people start-up to a global organization, yet we still focus on the same goal:
to become a true partner for our Clients, providing multidisciplinary support in their toughest research challenges.
We provide high-quality drug discovery and drug development services. We have the necessary expertise and know-how to support drug discovery projects across a broad range of therapeutic areas. We offer a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development.
2007
Served areaWorldwide
HeadquartersBobrzyńskiego 14, 30-348 Kraków – Poland
| Line item in (pln) | 22.03.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 90,886,840.00 | 218,795,827.00 | 455,923,000.00 | 584,911,000.00 |
| Noncurrent Assets | N/A | 44,942,779.00 | 75,826,002.00 | 276,798,000.00 | 381,829,000.00 |
| Property Plant And Equipment | N/A | 10,282,357.00 | 23,317,372.00 | 62,106,000.00 | 160,908,000.00 |
| Goodwill | N/A | 280,740.00 | 280,740.00 | 76,732,000.00 | 78,057,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 588,229.00 | 627,640.00 | 37,178,000.00 | 34,791,000.00 |
| Deferred Tax Assets | N/A | 8,520,949.00 | 12,339,284.00 | 11,776,000.00 | 10,094,000.00 |
| Other Noncurrent Assets | N/A | 343,335.00 | 345,235.00 | 829,000.00 | 1,060,000.00 |
| Current Assets | N/A | 45,944,061.00 | 142,969,825.00 | 179,125,000.00 | 203,082,000.00 |
| Inventories | N/A | 1,184,882.00 | 2,230,344.00 | 1,942,000.00 | 7,801,000.00 |
| Trade And Other Current Receivables | N/A | 25,854,362.00 | 33,997,866.00 | 65,616,000.00 | 98,802,000.00 |
| Other Current Financial Assets | N/A | 0.00 | 10,152,560.00 | 13,435,000.00 | 2,018,000.00 |
| Other Current Nonfinancial Assets | N/A | 1,010,222.00 | 1,069,264.00 | 4,263,000.00 | 5,100,000.00 |
| Cash and cash equivalents | 0.00 | 13,667,930.00 | 93,005,000.00 | 83,550,000.00 | 74,157,000.00 |
| Equity And Liabilities | N/A | 90,886,840.00 | 218,795,827.00 | 455,923,000.00 | 584,911,000.00 |
| Equity | 0.00 | 44,668,792.00 | 152,660,000.00 | 205,554,000.00 | 273,161,000.00 |
| Issued Capital | N/A | 12,876,983.00 | 14,684,379.00 | 14,684,000.00 | 14,684,000.00 |
| Retained Earnings | N/A | 0.00 | 5,523,002.00 | N/A | N/A |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | N/A | 14,899,000.00 | 30,309,000.00 |
| Retained Earnings Excluding Profit Loss For Reporting Period | N/A | N/A | N/A | 23,521,000.00 | 38,513,000.00 |
| Share Premium | N/A | 2,888,750.00 | 86,448,193.00 | 86,448,000.00 | 86,448,000.00 |
| Treasury Shares | N/A | N/A | N/A | 0.00 | 0.00 |
| Other Reserves | N/A | -2,988,750.00 | 0.00 | N/A | N/A |
| Capital Reserve | N/A | 22,993,414.00 | 22,993,414.00 | 22,994,000.00 | 22,994,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 41,231,445.00 | 147,298,404.00 | 196,870,000.00 | 262,178,000.00 |
| Noncontrolling Interests | N/A | 3,437,347.00 | 5,361,188.00 | 8,684,000.00 | 10,983,000.00 |
| Liabilities | N/A | 46,218,048.00 | 66,136,235.00 | 250,369,000.00 | 311,750,000.00 |
| Noncurrent Liabilities | N/A | 21,588,545.00 | 33,288,032.00 | 154,513,000.00 | 189,083,000.00 |
| Noncurrent Deferred Income Including Noncurrent Contract Liabilities | N/A | N/A | N/A | 2,043,000.00 | 11,020,000.00 |
| Deferred Tax Liabilities | N/A | 2,939,627.00 | 4,470,563.00 | 6,943,000.00 | 6,323,000.00 |
| Noncurrent Recognised Liabilities Defined Benefit Plan | N/A | 103,028.00 | 259,824.00 | 530,000.00 | 239,000.00 |
| Longterm Borrowings | N/A | N/A | N/A | 80,966,000.00 | 109,088,000.00 |
| Current Liabilities | N/A | 24,629,503.00 | 32,848,203.00 | 95,856,000.00 | 122,667,000.00 |
| Current Provisions | N/A | 0.00 | 0.00 | N/A | N/A |
| Trade And Other Current Payables | N/A | 11,001,479.00 | 10,428,959.00 | 31,331,000.00 | 49,185,000.00 |
| Current Contract Liabilities | N/A | 557,787.00 | 363,196.00 | 3,621,000.00 | 3,351,000.00 |
| Current Deferred Income Other Than Current Contract Liabilities | N/A | N/A | N/A | 855,000.00 | 2,120,000.00 |
| Accruals Classified As Current | N/A | 5,713,501.00 | 7,908,264.00 | 22,485,000.00 | 24,054,000.00 |
| Current Tax Liabilities Current | N/A | 229,198.00 | 416,458.00 | 2,762,000.00 | 2,493,000.00 |
| Line item in (pln) | 22.03.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 30,443,469.00 | 137,356,285.00 | 310,921,000.00 | 407,462,000.00 |
| Raw Materials And Consumables Used | 4,665,041.00 | 21,001,384.00 | 59,665,000.00 | 68,394,000.00 |
| Services Expense | 3,493,360.00 | 19,993,830.00 | 44,184,000.00 | 66,684,000.00 |
| Employee Benefits Expense | 14,344,783.00 | 65,198,967.00 | 121,527,000.00 | 155,991,000.00 |
| Expense From Sharebased Payment Transactions With Employees | N/A | N/A | 31,469,000.00 | 30,838,000.00 |
| Depreciation And Amortisation Expense | 2,629,819.00 | 13,525,722.00 | 27,488,000.00 | 36,828,000.00 |
| Tax Expense Other Than Income Tax Expense | 234,290.00 | 1,174,920.00 | 1,757,000.00 | 2,043,000.00 |
| Other Expense By Nature | 1,197,244.00 | 1,938,919.00 | 3,975,000.00 | 9,426,000.00 |
| Profit Loss From Operating Activities | 5,374,587.00 | 19,544,158.00 | 26,085,000.00 | 44,775,000.00 |
| Finance Income | 20,978.00 | 12,830.00 | 14,000.00 | 4,000.00 |
| Finance Costs | 501,341.00 | 703,132.00 | 5,031,000.00 | 4,572,000.00 |
| Profit Loss Before Tax | 4,894,224.00 | 18,853,856.00 | 21,068,000.00 | 40,207,000.00 |
| Income Tax Expense Continuing Operations | -909,976.00 | -1,068,063.00 | 2,846,000.00 | 7,599,000.00 |
| Profit Loss From Continuing Operations | 5,804,200.00 | 19,921,919.00 | N/A | N/A |
| Profit (loss) | 5,804,200.00 | 19,921,919.00 | 18,222,000.00 | 32,608,000.00 |
| Profit Loss Attributable To Owners Of Parent | 5,523,002.00 | 17,998,078.00 | 14,899,000.00 | 30,309,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 281,198.00 | 1,923,841.00 | 3,323,000.00 | 2,299,000.00 |
| Line item in (pln) | 22.03.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | 5,804,200.00 | 19,921,919.00 | 18,222,000.00 | 32,608,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 66,622.00 | -1,045,462.00 | 289,000.00 | -5,859,000.00 |
| Adjustments For Provisions | N/A | 40,669.00 | 1,687,732.00 | 13,028,000.00 | -911,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | -59,772.00 | -46,819.00 | 142,000.00 | 4,068,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | N/A | N/A | 31,469,000.00 | 30,838,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 4,338,804.00 | 29,356,203.00 | 85,406,000.00 | 75,430,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | N/A | N/A | 133,535,000.00 | 0.00 |
| Proceeds From Government Grants Classified As Investing Activities | N/A | N/A | N/A | 0.00 | 10,376,000.00 |
| Cash Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | 0.00 | 0.00 | N/A | N/A |
| Cash Receipts From Repayment Of Advances And Loans Made To Other Parties Classified As Investing Activities | N/A | 29,371.00 | 0.00 | N/A | N/A |
| Interest Received Classified As Investing Activities | N/A | 21,106.00 | 12,830.00 | 14,000.00 | 4,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 7,956,735.00 | -25,143,366.00 | -162,263,000.00 | -79,789,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 90,601,310.00 | N/A | N/A |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 6,989.00 | 4,641.00 | 101,801,000.00 | 37,844,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 34,464.00 | 6,989.00 | 9,173,000.00 | 11,296,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 1,528,138.00 | 9,613,784.00 | 22,245,000.00 | 28,024,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 60,746.00 | 626,146.00 | 3,801,000.00 | 4,196,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 1,372,391.00 | 75,124,561.00 | 66,819,000.00 | -5,672,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 13,667,930.00 | 79,337,398.00 | -10,038,000.00 | -10,031,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 0.00 | 583,000.00 | 638,000.00 |
| Cash and cash equivalents | 0.00 | 13,667,930.00 | 93,005,000.00 | 83,550,000.00 | 74,157,000.00 |
Please note that some sums might not add up.
PLSLVCR00029
LEI25940057WQ9YP5MOQF28
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.